A Tata Capital subsidiary was among the investors in a $27.4m round that will support development of Canscript, Mitra Biotech's oncology treatment analytics technology.
Mitra Biotech, a US-based cancer-focused biotechnology developer, has secured $27.4m in a series B round backed by conglomerate Tata’s Tata Capital Innovations Fund, according to LiveMint.
The round was co-led by Sequoia India and Sands Capital Ventures, with participation from RA Capital Management and Accel Partners.
The deal provided an exit to India Innovation Fund, which is managed by trade association Nasscom and research park IKP and backed by consultancy firm Tata Consultancy Services, telecommunications firm Airtel, IKP Trust and…
